Clinical Focus ›› 2026, Vol. 41 ›› Issue (8): 716-724.doi: 10.3969/j.issn.1004-583X.2026.08.008
Previous Articles Next Articles
Song Xufang(
), Chen Feifei, Wang Linfeng
Received:2026-06-10
Online:2026-08-20
Published:2026-08-25
Contact:
Song Xufang
E-mail:songxuff02@163.com
CLC Number:
Song Xufang, Chen Feifei, Wang Linfeng. Analysis of factors associated with cognitive impairment in patients with stage 5 chronic kidney disease undergoing hemodialysis and development of a risk prediction model[J]. Clinical Focus, 2026, 41(8): 716-724.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.08.008
| 项目 | 训练集(n=110) | 测试集(n=37) | 验证集(n=37) | F/Z/χ2值 | P值 |
|---|---|---|---|---|---|
| CI发生率[例(%)] | 36(32.73) | 12(32.43) | 12(32.43) | 0.002 | 0.999 |
| 年龄(岁) | 58.22±11.40 | 61.38±12.03 | 56.59±12.24 | 1.642 | 0.196 |
| 性别[例(%)] | |||||
| 男 女 | 66(60.00) 44(40.00) | 21(56.76) 16(43.24) | 23(62.16) 14(37.84) | 0.230 | 0.891 |
| 体质量指数(kg/m2) | 22.81±3.37 | 23.26±3.28 | 23.12±3.69 | 0.296 | 0.744 |
| 受教育年限(年) | 11.00(8.00, 13.00) | 11.00(9.00, 13.00) | 11.00(7.00, 14.00) | 0.101 | 0.951 |
| 原发疾病[例(%)] | |||||
| 糖尿病肾病 | 42(38.18) | 17(45.95) | 13(35.14) | ||
| 高血压肾损害 | 33(30.00) | 7(18.92) | 9(24.32) | 2.821 | 0.831 |
| 慢性肾小球肾炎 | 20(18.18) | 8(21.62) | 8(21.62) | ||
| 其他 | 15(13.64) | 5(13.51) | 7(18.92) | ||
| 并发症[例(%)] | |||||
| 高血压病 | 78(70.91) | 28(75.68) | 27(72.97) | 0.325 | 0.850 |
| 2型糖尿病 | 50(45.45) | 15(40.54) | 18(48.65) | 0.504 | 0.777 |
| 心力衰竭 | 31(28.18) | 8(21.62) | 15(40.54) | 3.373 | 0.185 |
| 透析参数 | |||||
| 透析龄(月) | 32.00(22.25, 45.00) | 32.00(24.00, 45.00) | 38.00(20.00, 51.00) | 0.688 | 0.709 |
| 高通量HD模式[例(%)] | 72(65.45) | 22(59.46) | 27(72.97) | 1.512 | 0.470 |
| 动静脉内瘘[例(%)] | 94(85.45) | 34(91.89) | 31(83.78) | 1.250 | 0.535 |
| IDWG(%) | 3.95(2.71, 4.80) | 3.63(2.79, 4.50) | 4.04(2.62, 4.89) | 0.920 | 0.631 |
| 超滤率[ml/(kg·h)] | 9.49±2.53 | 8.98±2.32 | 10.03±2.73 | 1.609 | 0.203 |
| 单室Kt/V | 1.45±0.20 | 1.46±0.20 | 1.50±0.21 | 0.811 | 0.446 |
| 尿素氮下降率(%) | 70.02±5.85 | 70.84±5.36 | 70.08±6.28 | 0.281 | 0.755 |
| 血清白蛋白(g/L) | 36.48±4.19 | 35.87±4.26 | 36.89±4.18 | 0.560 | 0.572 |
| 血红蛋白(g/L) | 108.36±11.87 | 108.98±12.00 | 108.09±12.57 | 0.055 | 0.946 |
| 血磷(mmol/L) | 2.20±0.18 | 2.20±0.19 | 2.19±0.18 | 0.061 | 0.941 |
| 血钙(mmol/L) | 1.95±0.54 | 1.93±0.55 | 1.88±0.54 | 0.190 | 0.827 |
| 全段甲状旁腺素(ng/L) | 52.03±15.22 | 49.25±13.35 | 53.94±17.02 | 0.891 | 0.412 |
| 碳酸氢盐(mmol/L) | 22.54±2.97 | 22.52±3.61 | 23.12±2.29 | 0.569 | 0.567 |
| 高敏C反应蛋白(mg/L) | 1.21(0.01, 6.73) | 2.64(0.01, 8.71) | 1.04(0.01, 5.85) | 1.681 | 0.431 |
| 同型半胱氨酸(μmol/L) | 25.60(18.96, 29.73) | 26.42(18.84, 30.71) | 24.78(16.76, 30.14) | 0.427 | 0.808 |
| 症状与事件[例(%)] | |||||
| 透析中低血压 | 28(25.45) | 8(21.62) | 10(27.03) | 0.318 | 0.853 |
| 不宁腿综合征 | 22(20.00) | 8(21.62) | 5(13.51) | 0.960 | 0.619 |
| 肌肉痉挛发生 | 31(28.18) | 9(24.32) | 10(27.03) | 0.209 | 0.901 |
| 头痛/恶心/呕吐 | 39(35.45) | 18(48.65) | 9(24.32) | 4.779 | 0.092 |
| 睡眠状况“差” | 44(40.00) | 13(35.14) | 15(40.54) | 0.314 | 0.855 |
| 跌倒史(近1月) | 11(10.00) | 1(2.70) | 4(10.81) | - | 0.408 |
| 营养状况“差” | 28(25.45) | 8(21.62) | 9(24.32) | 0.221 | 0.896 |
| 存在抑郁/焦虑情绪 | 37(33.64) | 12(32.43) | 13(35.14) | 0.061 | 0.970 |
| 药物使用[例(%)] | |||||
| 使用降压药 | 74(67.27) | 26(70.27) | 24(64.86) | 0.248 | 0.884 |
| 使用活性维生素D | 67(60.91) | 24(64.86) | 22(59.46) | 0.257 | 0.879 |
| 使用ACEI/ARB | 44(40.00) | 16(43.24) | 13(35.14) | 0.520 | 0.771 |
| 使用β受体阻滞剂 | 16(14.55) | 6(16.22) | 5(13.51) | 0.112 | 0.946 |
| 使用他汀类药物 | 77(70.00) | 25(67.57) | 27(72.97) | 0.259 | 0.878 |
Tab.1 Comparison of CI prevalence and baseline characteristics across different datasets
| 项目 | 训练集(n=110) | 测试集(n=37) | 验证集(n=37) | F/Z/χ2值 | P值 |
|---|---|---|---|---|---|
| CI发生率[例(%)] | 36(32.73) | 12(32.43) | 12(32.43) | 0.002 | 0.999 |
| 年龄(岁) | 58.22±11.40 | 61.38±12.03 | 56.59±12.24 | 1.642 | 0.196 |
| 性别[例(%)] | |||||
| 男 女 | 66(60.00) 44(40.00) | 21(56.76) 16(43.24) | 23(62.16) 14(37.84) | 0.230 | 0.891 |
| 体质量指数(kg/m2) | 22.81±3.37 | 23.26±3.28 | 23.12±3.69 | 0.296 | 0.744 |
| 受教育年限(年) | 11.00(8.00, 13.00) | 11.00(9.00, 13.00) | 11.00(7.00, 14.00) | 0.101 | 0.951 |
| 原发疾病[例(%)] | |||||
| 糖尿病肾病 | 42(38.18) | 17(45.95) | 13(35.14) | ||
| 高血压肾损害 | 33(30.00) | 7(18.92) | 9(24.32) | 2.821 | 0.831 |
| 慢性肾小球肾炎 | 20(18.18) | 8(21.62) | 8(21.62) | ||
| 其他 | 15(13.64) | 5(13.51) | 7(18.92) | ||
| 并发症[例(%)] | |||||
| 高血压病 | 78(70.91) | 28(75.68) | 27(72.97) | 0.325 | 0.850 |
| 2型糖尿病 | 50(45.45) | 15(40.54) | 18(48.65) | 0.504 | 0.777 |
| 心力衰竭 | 31(28.18) | 8(21.62) | 15(40.54) | 3.373 | 0.185 |
| 透析参数 | |||||
| 透析龄(月) | 32.00(22.25, 45.00) | 32.00(24.00, 45.00) | 38.00(20.00, 51.00) | 0.688 | 0.709 |
| 高通量HD模式[例(%)] | 72(65.45) | 22(59.46) | 27(72.97) | 1.512 | 0.470 |
| 动静脉内瘘[例(%)] | 94(85.45) | 34(91.89) | 31(83.78) | 1.250 | 0.535 |
| IDWG(%) | 3.95(2.71, 4.80) | 3.63(2.79, 4.50) | 4.04(2.62, 4.89) | 0.920 | 0.631 |
| 超滤率[ml/(kg·h)] | 9.49±2.53 | 8.98±2.32 | 10.03±2.73 | 1.609 | 0.203 |
| 单室Kt/V | 1.45±0.20 | 1.46±0.20 | 1.50±0.21 | 0.811 | 0.446 |
| 尿素氮下降率(%) | 70.02±5.85 | 70.84±5.36 | 70.08±6.28 | 0.281 | 0.755 |
| 血清白蛋白(g/L) | 36.48±4.19 | 35.87±4.26 | 36.89±4.18 | 0.560 | 0.572 |
| 血红蛋白(g/L) | 108.36±11.87 | 108.98±12.00 | 108.09±12.57 | 0.055 | 0.946 |
| 血磷(mmol/L) | 2.20±0.18 | 2.20±0.19 | 2.19±0.18 | 0.061 | 0.941 |
| 血钙(mmol/L) | 1.95±0.54 | 1.93±0.55 | 1.88±0.54 | 0.190 | 0.827 |
| 全段甲状旁腺素(ng/L) | 52.03±15.22 | 49.25±13.35 | 53.94±17.02 | 0.891 | 0.412 |
| 碳酸氢盐(mmol/L) | 22.54±2.97 | 22.52±3.61 | 23.12±2.29 | 0.569 | 0.567 |
| 高敏C反应蛋白(mg/L) | 1.21(0.01, 6.73) | 2.64(0.01, 8.71) | 1.04(0.01, 5.85) | 1.681 | 0.431 |
| 同型半胱氨酸(μmol/L) | 25.60(18.96, 29.73) | 26.42(18.84, 30.71) | 24.78(16.76, 30.14) | 0.427 | 0.808 |
| 症状与事件[例(%)] | |||||
| 透析中低血压 | 28(25.45) | 8(21.62) | 10(27.03) | 0.318 | 0.853 |
| 不宁腿综合征 | 22(20.00) | 8(21.62) | 5(13.51) | 0.960 | 0.619 |
| 肌肉痉挛发生 | 31(28.18) | 9(24.32) | 10(27.03) | 0.209 | 0.901 |
| 头痛/恶心/呕吐 | 39(35.45) | 18(48.65) | 9(24.32) | 4.779 | 0.092 |
| 睡眠状况“差” | 44(40.00) | 13(35.14) | 15(40.54) | 0.314 | 0.855 |
| 跌倒史(近1月) | 11(10.00) | 1(2.70) | 4(10.81) | - | 0.408 |
| 营养状况“差” | 28(25.45) | 8(21.62) | 9(24.32) | 0.221 | 0.896 |
| 存在抑郁/焦虑情绪 | 37(33.64) | 12(32.43) | 13(35.14) | 0.061 | 0.970 |
| 药物使用[例(%)] | |||||
| 使用降压药 | 74(67.27) | 26(70.27) | 24(64.86) | 0.248 | 0.884 |
| 使用活性维生素D | 67(60.91) | 24(64.86) | 22(59.46) | 0.257 | 0.879 |
| 使用ACEI/ARB | 44(40.00) | 16(43.24) | 13(35.14) | 0.520 | 0.771 |
| 使用β受体阻滞剂 | 16(14.55) | 6(16.22) | 5(13.51) | 0.112 | 0.946 |
| 使用他汀类药物 | 77(70.00) | 25(67.57) | 27(72.97) | 0.259 | 0.878 |
| 项目 | no-CI组(n=74) | CI组(n=36) | t/Z/χ2值 | P值 |
|---|---|---|---|---|
| 年龄(岁) | 55.50±11.44 | 63.81±9.18 | 3.800 | <0.01 |
| 性别[例(%)] | ||||
| 男 女 | 46(62.16) 28(37.84) | 20(55.56) 16(44.44) | 0.440 | 0.507 |
| 体质量指数(kg/m2) | 23.20±3.10 | 22.00±3.80 | 1.766 | 0.080 |
| 受教育年限(年) | 12.00(7.00, 14.00) | 9.00(6.00, 11.25) | 3.494 | <0.01 |
| 原发疾病[例(%)] | ||||
| 糖尿病肾病 | 22(29.73) | 20(55.56) | ||
| 高血压肾损害 | 24(32.43) | 9(25.00) | - | 0.075 |
| 慢性肾小球肾炎 | 16(21.62) | 4(11.11) | ||
| 并发症[例(%)] | ||||
| 高血压病 | 45(60.81) | 33(91.67) | 11.178 | 0.001 |
| 2型糖尿病 | 28(37.84) | 22(61.11) | 5.291 | 0.021 |
| 心力衰竭 | 18(24.32) | 13(36.11) | 1.662 | 0.197 |
| 透析参数 | ||||
| 透析龄(月) | 26.00(20.00, 38.75) | 44.50(32.00, 61.75) | -4.955 | <0.01 |
| 高通量HD模式[例(%)] | 24(32.43) | 14(38.89) | 0.446 | 0.504 |
| 动静脉内瘘[例(%)] | 66(89.19) | 28(77.78) | 2.537 | 0.111 |
| IDWG(%) | 3.46(2.64, 4.60) | 4.06(3.44, 4.99) | -1.653 | 0.098 |
| 超滤率[ml/(kg·h)] | 9.10±2.30 | 10.30±2.80 | -2.388 | 0.019 |
| 单室Kt/V | 1.48±0.19 | 1.40±0.22 | 1.967 | 0.052 |
| 尿素氮下降率(%) | 71.00±5.28 | 68.00±6.51 | 2.587 | 0.011 |
| 血清白蛋白(g/L) | 37.30±3.80 | 34.80±4.50 | 3.045 | 0.003 |
| 血红蛋白(g/L) | 110.00±11.00 | 105.00±13.00 | 2.106 | 0.038 |
| 血磷(mmol/L) | 2.21±0.17 | 2.18±0.20 | 0.845 | 0.400 |
| 血钙(mmol/L) | 1.87±0.50 | 2.10±0.60 | -2.110 | 0.037 |
| 全段甲状旁腺素(ng/L) | 50.10±14.10 | 56.00±16.80 | -1.932 | 0.056 |
| 碳酸氢盐(mmol/L) | 22.90±2.80 | 21.80±3.20 | 1.843 | 0.068 |
| 高敏C反应蛋白(mg/L) | 0.26(0.01, 3.99) | 5.73(2.34, 9.51) | -3.168 | 0.002 |
| 同型半胱氨酸(μmol/L) | 23.20±7.60 | 28.50±9.10 | -3.213 | 0.002 |
| 症状与事件[例(%)] | ||||
| 透析中低血压 | 13(17.57) | 15(41.67) | 7.412 | 0.006 |
| 不宁腿综合征 | 12(16.22) | 10(27.78) | 2.023 | 0.155 |
| 肌肉痉挛发生 | 17(22.97) | 14(38.89) | 3.031 | 0.082 |
| 头痛/恶心/呕吐 | 21(28.38) | 18(50.00) | 4.947 | 0.026 |
| 睡眠状况“差” | 22(29.73) | 22(61.11) | 9.937 | 0.002 |
| 跌倒史(近1月) | 5(6.76) | 6(16.67) | 1.656 | 0.198 |
| 营养状况“差” | 14(18.92) | 14(38.89) | 5.090 | 0.024 |
| 存在抑郁/焦虑情绪 | 19(25.68) | 18(50.00) | 6.419 | 0.011 |
| 药物使用[例(%)] | ||||
| 使用降压药 | 45(60.81) | 29(80.56) | 4.288 | 0.038 |
| 使用活性维生素D | 42(56.76) | 25(69.44) | 1.637 | 0.201 |
| 使用ACEI/ARB | 32(43.24) | 12(33.33) | 0.991 | 0.320 |
| 使用β受体阻滞剂 | 6(8.11) | 10(27.78) | 7.538 | 0.006 |
| 使用他汀类药物 | 49(66.22) | 28(77.78) | 1.542 | 0.214 |
Tab.2 Univariate analysis of CI in patients in the training set
| 项目 | no-CI组(n=74) | CI组(n=36) | t/Z/χ2值 | P值 |
|---|---|---|---|---|
| 年龄(岁) | 55.50±11.44 | 63.81±9.18 | 3.800 | <0.01 |
| 性别[例(%)] | ||||
| 男 女 | 46(62.16) 28(37.84) | 20(55.56) 16(44.44) | 0.440 | 0.507 |
| 体质量指数(kg/m2) | 23.20±3.10 | 22.00±3.80 | 1.766 | 0.080 |
| 受教育年限(年) | 12.00(7.00, 14.00) | 9.00(6.00, 11.25) | 3.494 | <0.01 |
| 原发疾病[例(%)] | ||||
| 糖尿病肾病 | 22(29.73) | 20(55.56) | ||
| 高血压肾损害 | 24(32.43) | 9(25.00) | - | 0.075 |
| 慢性肾小球肾炎 | 16(21.62) | 4(11.11) | ||
| 并发症[例(%)] | ||||
| 高血压病 | 45(60.81) | 33(91.67) | 11.178 | 0.001 |
| 2型糖尿病 | 28(37.84) | 22(61.11) | 5.291 | 0.021 |
| 心力衰竭 | 18(24.32) | 13(36.11) | 1.662 | 0.197 |
| 透析参数 | ||||
| 透析龄(月) | 26.00(20.00, 38.75) | 44.50(32.00, 61.75) | -4.955 | <0.01 |
| 高通量HD模式[例(%)] | 24(32.43) | 14(38.89) | 0.446 | 0.504 |
| 动静脉内瘘[例(%)] | 66(89.19) | 28(77.78) | 2.537 | 0.111 |
| IDWG(%) | 3.46(2.64, 4.60) | 4.06(3.44, 4.99) | -1.653 | 0.098 |
| 超滤率[ml/(kg·h)] | 9.10±2.30 | 10.30±2.80 | -2.388 | 0.019 |
| 单室Kt/V | 1.48±0.19 | 1.40±0.22 | 1.967 | 0.052 |
| 尿素氮下降率(%) | 71.00±5.28 | 68.00±6.51 | 2.587 | 0.011 |
| 血清白蛋白(g/L) | 37.30±3.80 | 34.80±4.50 | 3.045 | 0.003 |
| 血红蛋白(g/L) | 110.00±11.00 | 105.00±13.00 | 2.106 | 0.038 |
| 血磷(mmol/L) | 2.21±0.17 | 2.18±0.20 | 0.845 | 0.400 |
| 血钙(mmol/L) | 1.87±0.50 | 2.10±0.60 | -2.110 | 0.037 |
| 全段甲状旁腺素(ng/L) | 50.10±14.10 | 56.00±16.80 | -1.932 | 0.056 |
| 碳酸氢盐(mmol/L) | 22.90±2.80 | 21.80±3.20 | 1.843 | 0.068 |
| 高敏C反应蛋白(mg/L) | 0.26(0.01, 3.99) | 5.73(2.34, 9.51) | -3.168 | 0.002 |
| 同型半胱氨酸(μmol/L) | 23.20±7.60 | 28.50±9.10 | -3.213 | 0.002 |
| 症状与事件[例(%)] | ||||
| 透析中低血压 | 13(17.57) | 15(41.67) | 7.412 | 0.006 |
| 不宁腿综合征 | 12(16.22) | 10(27.78) | 2.023 | 0.155 |
| 肌肉痉挛发生 | 17(22.97) | 14(38.89) | 3.031 | 0.082 |
| 头痛/恶心/呕吐 | 21(28.38) | 18(50.00) | 4.947 | 0.026 |
| 睡眠状况“差” | 22(29.73) | 22(61.11) | 9.937 | 0.002 |
| 跌倒史(近1月) | 5(6.76) | 6(16.67) | 1.656 | 0.198 |
| 营养状况“差” | 14(18.92) | 14(38.89) | 5.090 | 0.024 |
| 存在抑郁/焦虑情绪 | 19(25.68) | 18(50.00) | 6.419 | 0.011 |
| 药物使用[例(%)] | ||||
| 使用降压药 | 45(60.81) | 29(80.56) | 4.288 | 0.038 |
| 使用活性维生素D | 42(56.76) | 25(69.44) | 1.637 | 0.201 |
| 使用ACEI/ARB | 32(43.24) | 12(33.33) | 0.991 | 0.320 |
| 使用β受体阻滞剂 | 6(8.11) | 10(27.78) | 7.538 | 0.006 |
| 使用他汀类药物 | 49(66.22) | 28(77.78) | 1.542 | 0.214 |
Fig.4 Nomogram for the occurrence of CI in patients with stage 5 chronic kidney disease undergoing hemodialysis Note: On the top “Points” scale of the nomogram, draw a vertical line upward from each patient’s actual value for each risk factor to obtain the corresponding score, and sum all scores to obtain the total score. The total score of this model ranges from 0 to 400 points, corresponding to the bottom “Total Points” scale. Then, draw a vertical line downward from the total score point to intersect the lowest prediction probability axis, where the predicted probability of future CI in the patient can be read.
Fig.6 Calibration curves and decision curve analysis across different datasets a. Calibration curve of the training set; b. Calibration curve of the test set; c. Decision curve analysis of the training set; d. Decision curve analysis of the test set
| [1] | Hassanein EHM, Ibrahim IM, Abd-Alhameed EK, et al. Nrf2/HO-1 as a therapeutic target in renal fibrosis[J]. Life Sci, 2023, 334:122209. doi: 10.1016/j.lfs.2023.122209. |
| [2] | Andrews TD, Day GS, Irani SR, et al. Uremic toxins, CKD, and cognitive dysfunction[J]. J Am Soc Nephrol, 2025, 36(6):1208-1226. doi: 10.1681/ASN.0000000675. |
| [3] |
Capasso G, Franssen CFM, Perna AF, et al. Drivers and mechanisms of cognitive decline in chronic kidney disease[J]. Nat Rev Nephrol, 2025, 21(8):536-552. doi: 10.1038/s41581-025-00963-0.
pmid: 40281076 |
| [4] |
Bobot M, Burtey S. New insights into mechanisms underlying cognitive impairment in chronic kidney disease[J]. Kidney Int, 2024, 106(6):1020-1022. doi: 10.1016/j.kint.2024.09.008.
pmid: 39577985 |
| [5] |
Chan FHF, Lim PXH, Zhu X, et al. Patient and health care provider perspectives of cognitive difficulties in dialysis[J]. Kidney Int Rep, 2025, 10(6):1771-1783. doi: 10.1016/j.ekir.2025.03.056.
pmid: 40630306 |
| [6] | 上海慢性肾脏病早发现及规范化诊治与示范项目专家组. 慢性肾脏病筛查诊断及防治指南[J]. 中国实用内科杂志, 2017, 37(1):28-34. doi: 10.19538/j.nk2017010108. |
| [7] |
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
pmid: 34556256 |
| [8] | Yu J, Li Y, Zhu B, et al. Research progress on the kidney-gut-brain axis in brain dysfunction in maintenance hemodialysis patients[J]. Front Med (Lausanne), 2025, 12:1538048. doi: 10.3389/fmed.2025.1538048. |
| [9] | Hermann DM, Kribben A, Bruck H. Cognitive impairment in chronic kidney disease: Clinical findings, risk factors and consequences for patient care[J]. J Neural Transm (Vienna), 2014, 121(6):627-632. doi: 10.1007/s00702-014-1160-z. |
| [10] | 张慧, 周紫娟, 杨薇, 等. 终末期肾病患者轻度认知功能障碍影响因素的探究——基于logistic和决策树模型[J]. 中国血液净化, 2023, 22(11):876-880. doi:10.3969/j.issn.1671-4091.2023.11.017. |
| [11] | 周雨婷, 林亚妹, 王娜, 等. 老年维持性血液透析患者认知功能障碍发生情况及影响因素分析[J]. 海军医学杂志, 2020, 41(5):568-571. doi:10.3969/j.issn.1009-0754.2020.05.027. |
| [12] | Chandana S, M J, Suresh S, et al. Cognitive decline in hemodialysis patients: A Cross-sectional study using addenbrooke's cognitive examination-III (ACE-III)[J]. Cureus, 2025, 17(9):e92326. doi: 10.7759/cureus.92326. |
| [13] | 蒋建新, 茹江丽, 焦宏宇, 等. 慢性肾衰竭病人血液透析后发生认知障碍的预测模型构建与验证[J]. 护理研究, 2023, 37(21):3838-3844. doi:10.12102/j.issn.1009-6493.2023.21.008. |
| [14] | Holm H, Ricci F, Di Martino G, et al. Beta-blocker therapy and risk of vascular dementia: A population-based prospective study[J]. Vascul Pharmacol, 2020, 125-126:106649. doi: 10.1016/j.vph.2020.106649. |
| [15] |
Evans AK, Park HH, Saw NL, et al. Age-related neuroinflammation and pathology in the locus coeruleus and hippocampus: Beta-adrenergic antagonists exacerbate impairment of learning and memory in aged mice[J]. Neurobiol Aging, 2021, 106:241-256. doi: 10.1016/j.neurobiolaging.2021.06.012.
pmid: 34320462 |
| [16] | 马万瑞, 李漫娜, 王立群, 等. ≥55岁高血压患者发生轻度认知功能障碍的影响因素研究[J]. 中国全科医学, 2023, 26(9):1075-1079+1085. doi:10.12114/j.issn.1007-9572.2022.0733. |
| [17] | 赵世亮, 牛艳国, 赵燕民, 等. 颅内动脉瘤介入术后认知功能障碍的因素探讨:基于PSM法[J]. 临床荟萃, 2025, 40(4):320-324. doi:10.3969/j.issn.1004-583X.2025.04.004. |
| [18] | 赵晓月, 王洁, 黄小睿. 慢性肾脏病5期患者认知功能障碍风险因素研究进展[J]. 右江民族医学院学报, 2024, 46(6):996-1001. doi:10.3969/j.issn.1001-5817.2024.06.028. |
| [19] | 王冰莹, 王楠. 维持性血液透析患者认知功能障碍预测模型构建的研究进展[J]. 临床肾脏病杂志, 2025, 25(9):798-802. doi:10.3969/j.issn.1671-2390.2025.09.010. |
| [20] | 廖萌萌, 吴小斌. 经皮穴位电刺激预防术后谵妄和术后认知功能障碍的研究进展[J]. 中国医学创新, 2025, 22(13):175-179. doi:10.3969/j.issn.1674-4985.2025.13.039. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||